Medtronic (MDT) Net Equity Issued and Repurchased (2014 - 2026)

Medtronic (MDT) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $97.0 million in Q2 2026.

• For the quarter ending Q2 2026, Net Equity Issued and Repurchased fell 10.19% year-over-year to $97.0 million; the trailing twelve-month figure through Apr 2026 stood at $516.0 million (up 1.57% YoY), and the FY2026 full-year result was $516.0 million, up 1.57% from the prior year.
• Net Equity Issued and Repurchased eased to $97.0 million in Q2 2026, from $164.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $168.0 million in Q1 2025 to a low of $43.0 million in Q3 2022.
• A 5-year average of $98.4 million and a median of $92.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased sank 64.1% in 2022 and jumped 194.74% in 2025, its largest moves.
• Tracing MDT's Net Equity Issued and Repurchased over 5 years: stood at $110.0 million in 2022, then tumbled by 34.55% to $72.0 million in 2023, then surged by 98.61% to $143.0 million in 2024, then increased by 11.89% to $160.0 million in 2025, then plunged by 39.38% to $97.0 million in 2026.
• Business Quant data shows MDT's Net Equity Issued and Repurchased at $97.0 million in Q2 2026, $164.0 million in Q1 2026, and $160.0 million in Q4 2025.